Pharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug ...

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

Air Canada says it now plans to resume flights on Monday evening after a planned resumption of service on Sunday afternoon ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Novo Nordisk (NVO, Financials) shares climbed nearly 5% Monday after the U.S. Food and Drug Administration granted ...

In the first 24 hours after Lilly's announcement, Ozempic sales rose by 400 per cent, according to weight loss jab provider CheqUp.

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

Dow Jones Top Company Headlines at 9 AM ET: Air Canada Halts Guidance as Flight Attendant Strike Continues | Soho ... Air Canada withdrew its financial targets Monday for the year as a strike by ...

Wegovy becomes the first GLP-1 based therapy authorized for MASH, which affects roughly 5% of U.S. adults, according to the ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.